All sponsors

Gilead Sciences $GILD

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS58
PHASE 3 / 2-327
RECRUITING16
READOUTS ≤12 MONTHS11
READOUT SLIPPED >6 MO54%

Delay Index: of 46 active trials registered more than a year ago, 25 have moved their primary completion (readout) date by more than 6 months since first registration (median +7.7 months). See all sponsors →

Open Gilead Sciences on the live radar map → 📅 $GILD readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Tenofovir DF
NCT01651403
P3Active, not recruitingChronic Hepatitis B902017-08-07 (+25 mo)
CAPELLA
NCT04150068
P2/3Active, not recruitingHIV-1-infection722020-10-05 (-7 mo)
Sacituzumab Govitecan-hziy
NCT04454437
P2Active, not recruitingMetastatic Triple-negative Breast Cancer802021-08-06 (-3 mo)
EVOKE-01
NCT05089734
P3Active, not recruitingNon-Small Cell Lung Cancer6032023-11-29 (-5 mo)
ISL
NCT05052996
P2Active, not recruitingHIV-1 Infection1422023-12-19 (+17 mo)
PURPOSE 1
NCT04994509
P3Active, not recruitingPre-Exposure Prophylaxis of HIV Infection53682024-05-27 (+3 mo)
Teropavimab
NCT05729568
P2Active, not recruitingHIV-1 Infection832024-07-02 (-9 mo)
PURPOSE 2
NCT04925752
P3Active, not recruitingPre-Exposure Prophylaxis of HIV Infection32922024-08-21 (+8 mo)
TROPiCS-03
NCT03964727
P2Active, not recruitingMetastatic Solid Tumor2272025-01-15 (+34 mo)
B/F/TAF (Adult Strength)
NCT02881320
P2/3Active, not recruitingHIV-1 Infection1772025-03-24 (+94 mo)
ATV
NCT02016924
P2/3Active, not recruitingAcquired Immune Deficiency Syndrome (AIDS); HIV Infections1332025-06-13 (+94 mo)
ARTISTRY-1
NCT05502341
P2/3Active, not recruitingHIV-1-infection6892025-09-29 (-3 mo)
ARTISTRY-2
NCT06333808
P3Active, not recruitingHIV-1-infection5772025-10-27 (-1 mo)
SWIFT
NCT06290934
P2Active, not recruitingUlcerative Colitis2282026-03-04 (-14 mo)
ISLEND-1
NCT06630286
P3Active, not recruitingHIV-1-infection6092026-04-17 (-1 mo)
ISLEND-2
NCT06630299
P3Active, not recruitingHIV-1-Infection6002026-04-23 (-13 mo)
PURPOSE 5
NCT06513312
P2Active, not recruitingPre-Exposure Prophylaxis of HIV Infection2682026-05-28 (-7 mo)
PURPOSE 3
NCT06101329
P2Active, not recruitingPre-Exposure Prophylaxis of HIV Infection2532026-07-22 (-11 mo)
PURPOSE 4
NCT06101342
P2Active, not recruitingPre-Exposure Prophylaxis of HIV Infection1812026-07-27 (-11 mo)
Sacituzumab Govitecan-hziy
NCT05119907
P2Active, not recruitingSolid Tumor532026-10 (+47 mo)
TAF
NCT02932150
P2Active, not recruitingChronic Hepatitis B1502026-10-27 (+89 mo)
Sacituzumab Govitecan-hziy
NCT04639986
P3Active, not recruitingMetastatic Breast Cancer3312026-12 (+48 mo)
PALEKONA
NCT06029972
P2Active, not recruitingUlcerative Colitis1762027-01 (+19 mo)
ASCENT-04
NCT05382286
P3Active, not recruitingTriple Negative Breast Cancer; PD-L1 Positive4432027-02
EVOKE-02
NCT05186974
P2Active, not recruitingNon-small Cell Lung Cancer1932027-03 (+46 mo)
Oral Lenacapavir
NCT06749054
P2RecruitingHIV-1-infection122027-03 (+12 mo)
VELOCITY-HNSCC
NCT06727565
P2Active, not recruitingHead and Neck Squamous Cell Carcinoma392027-03 (+7 mo)
ASCENT-J02
NCT05101096
P1/2Active, not recruitingAdvanced Solid Tumor; Metastatic Triple-Negative Breast Cancer1352027-05 (+50 mo)
Sacituzumab govitecan-hziy (SG)
NCT05633654
P3RecruitingTriple Negative Breast Cancer15142027-06
B/F/TAF
NCT07841990
P2RecruitingHIV-1 Infection1252027-08
GS-3242 Tablet
NCT07645287
P2RecruitingHIV-1-infection1752027-08
GS-1179
NCT07912996
P2Not yet recruitingHSV-2 Infection3002027-11
NAPISTAR1-01
NCT06303505
P1/2RecruitingOvarian Cancer; Non-small Cell Lung Cancer3342027-12 (+11 mo)
EDGE-Lung
NCT05676931
P2Active, not recruitingAdvanced Non-Small Cell Lung Cancer4002027-12 (+15 mo)
WONDERS1
NCT06544733
P2/3Active, not recruitingHIV-1-Infection6752028-01
OC
NCT07736937
P1/2RecruitingOvarian Cancer722028-03
ASCENT-07
NCT05840211
P3Active, not recruitingLocally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer6542028-04 (+31 mo)
Sacituzumab Govitecan-hziy (SG)
NCT06926920
P1/2RecruitingTriple Negative Breast Cancer1002028-06
STAR-121
NCT05502237
P3Active, not recruitingNon-small Cell Lung Cancer10212028-06 (+6 mo)
ASCENT-03
NCT05382299
P3Active, not recruitingTriple Negative Breast Cancer; PD-L1 Negative6232028-07 (+14 mo)
PURPOSE 365
NCT07047716
P3Active, not recruitingHIV Pre-exposure Prophylaxis3392028-09
Seladelpar 5 mg Capsule
NCT03301506
P3Active, not recruitingPrimary Biliary Cirrhosis3402028-11 (+95 mo)
Denikitug
NCT07527858
P2RecruitingAdvanced Microsatellite Stable Colorectal Cancer1702028-12
Seladelpar
NCT07841977
P2RecruitingPrimary Biliary Cholangitis1322028-12
TUB-030
NCT06657222
P1/2RecruitingAdvanced Solid Tumors; HNSCC2502028-12
Lenacapavir
NCT07682961
P3RecruitingHIV Infections5902029-03
Lenacapavir
NCT07683000
P3RecruitingHIV-1-infection5902029-03
TUB-040
NCT07806773
P2Not yet recruitingNSCLC; Non Small Cell Lung Cancer802029-05
ASCENT-GYN-01
NCT06486441
P3Active, not recruitingEndometrial Cancer6402029-06
VELOCITY-Lung
NCT05633667
P2Active, not recruitingLung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer1922029-09 (+32 mo)
NAPISTAR 1-03
NCT07743541
P1/2Not yet recruitingUterine Endometrial Cancer1002029-09
EVOKE-SCLC-04
NCT06801834
P3RecruitingExtensive Stage Small Cell Lung Cancer (ES-SCLC)6952029-10
Denikitug
NCT07546812
P2Active, not recruitingHER2-negative; Gastroesophageal Junction1202030-01
GS-4321
NCT07096193
P1/2RecruitingChronic Hepatitis Delta2002030-01 (+41 mo)
TROPHY U-01
NCT03547973
P2Active, not recruitingMetastatic Urothelial Cancer5022030-04 (+119 mo)
Lenacapavir
NCT06532656
P2/3Active, not recruitingHIV-1-infection752030-07 (+29 mo)
AFFIRM
NCT06051617
P3RecruitingPrimary Biliary Cholangitis4022030-08 (+13 mo)
GS-3242 Tablet
NCT07708727
P2/3RecruitingHIV-1-infection7002030-10